Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Aug 2018
ReviewNew developments in systemic therapy for advanced biliary tract cancer.
Biliary tract cancer, carcinoma of the extrahepatic bile ducts, carcinoma of the gall bladder, ampullary carcinoma and intrahepatic cholangiocarcinoma are often identified at an advanced stage and have poor prognoses. Although effective chemotherapy regimens are needed, their development remains unsatisfactory. From the results of a phase III clinical trial (ABC-02 trial), gemcitabine plus cisplatin is the standard first-line chemotherapeutic regimen for advanced biliary tract cancer. ⋯ FGFR2 fusion gene, mutations of IDH1/2, BRAF, BRCA1/2, ATM, PIK3CA and overexpression of c-MET and HER2/neu are reported relatively frequently and are interesting targets. Therefore, future development in precision medicine utilizing next-generation sequencing is expected. Although the efficacy of immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1 and anti-CTLA4 antibodies, remains unknown at present, basic data and results of ongoing clinical trials are anticipated.
-
Jpn. J. Clin. Oncol. · Aug 2018
Clinical TrialPalliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis.
To investigate the pain relief effect and safety of percutaneous radiofrequency ablation (RFA) with a multitined electrode combined with cement injection in patients with painful metastatic bone tumors. ⋯ RFA with or without bone cement is safe and effective in the palliative treatment of pain caused by metastatic bone tumors.